Literature DB >> 2170511

An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma.

A C Lawrence1, G Evin, A Kladis, D J Campbell.   

Abstract

We describe here a method of measuring angiotensin peptides and their carboxy-truncated metabolites in human plasma using N-terminal-directed antisera. Antisera raised against N-acetylated angiotensin (Ang) II and N-acetylated Ang III analogues were used to develop two radioimmunoassays. Extracted plasma samples were acetylated prior to separation of cross-reacting angiotensin peptides by high-performance liquid chromatography (HPLC). Fractions were assayed with both antisera to obtain measurements for eight angiotensin peptides. Angiotensin levels measured in normal males were (fmol/ml plasma, mean +/- s.e.m., n = 14): Ang-(1-7) 1.0 +/- 0.2, Ang II 13.9 +/- 2.0, Ang-(1-9) less than 0.4, Ang I 19.5 +/- 2.4, Ang-(2-7) less than 1.1, Ang III 2.9 +/- 1.0, Ang-(2-9) less than 2.1, Ang-(2-10) 2.4 +/- 0.8. Hypertensive patients receiving angiotensin converting enzyme (ACE) inhibitor therapy (n = 8) had an increase in Ang I to 187.3 +/- 107.2 fmol/ml (P = 0.002), and a reduction in Ang II to 4.8 +/- 1.2 fmol/ml (P less than 0.001). Furthermore, these patients showed a ninefold increase in Ang-(1-7) to 9.7 +/- 4.3 fmol/ml (P less than 0.001), indicating a role for prolylendopeptidase in the metabolism of Ang I in vivo. These N-terminal assays have demonstrated that carboxy-truncated metabolites of Ang I and Ang II make little contribution to plasma angiotensin peptides, except during ACE inhibitor therapy. Furthermore, these antisera allow the measurement of Ang I and Ang II in the same radioimmunoassay of fractions from HPLC, providing a highly reliable estimate of the Ang II:Ang I ratio.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2170511     DOI: 10.1097/00004872-199008000-00005

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  12 in total

1.  Determinants of CREB degradation and KChIP2 gene transcription in cardiac memory.

Authors:  Nazira Ozgen; David H Lau; Iryna N Shlapakova; Warren Sherman; Steven J Feinmark; Peter Danilo; Michael R Rosen
Journal:  Heart Rhythm       Date:  2010-03-24       Impact factor: 6.343

Review 2.  Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?

Authors:  Mark C Chappell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-16       Impact factor: 4.733

3.  Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries.

Authors:  Matthew J Durand; Gábor Raffai; Brian D Weinberg; Julian H Lombard
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-23       Impact factor: 4.733

Review 4.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 5.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

6.  Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.

Authors:  Gillian I Rice; Daniel A Thomas; Peter J Grant; Anthony J Turner; Nigel M Hooper
Journal:  Biochem J       Date:  2004-10-01       Impact factor: 3.857

7.  Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas.

Authors:  Robson A S Santos; Ana C Simoes e Silva; Christine Maric; Denise M R Silva; Raquel Pillar Machado; Insa de Buhr; Silvia Heringer-Walther; Sergio Veloso B Pinheiro; Myriam Teresa Lopes; Michael Bader; Elizabeth P Mendes; Virgina Soares Lemos; Maria Jose Campagnole-Santos; Heinz-Peter Schultheiss; Robert Speth; Thomas Walther
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 11.205

8.  Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor.

Authors:  D Chauveau; T T Guyenne; F Cumin; G Chatellier; P Corvol; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

9.  Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies.

Authors:  Uma Anand; Yiangos Yiangou; Marco Sinisi; Michael Fox; Anthony MacQuillan; Tom Quick; Yuri E Korchev; Chas Bountra; Tom McCarthy; Praveen Anand
Journal:  Mol Pain       Date:  2015-06-26       Impact factor: 3.395

10.  Newly developed radioimmunoassay for Human Angiotensin-(1-12) measurements in plasma and urine.

Authors:  Sarfaraz Ahmad; Henry A Punzi; Kendra N Wright; Leanne Groban; Carlos M Ferrario
Journal:  Mol Cell Endocrinol       Date:  2021-03-30       Impact factor: 4.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.